Cargando…

Safety and efficacy of Vonoprazan-based triple therapy against Helicobacter pylori infection: A single-center experience with 1118 patients

Detalles Bibliográficos
Autores principales: Fukuda, Daisuke, Akazawa, Yuko, Takeshima, Fuminao, Nakao, Kazuhiko, Fukuda, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984333/
https://www.ncbi.nlm.nih.gov/pubmed/27582888
http://dx.doi.org/10.1177/1756283X16654499
_version_ 1782447958384443392
author Fukuda, Daisuke
Akazawa, Yuko
Takeshima, Fuminao
Nakao, Kazuhiko
Fukuda, Yutaka
author_facet Fukuda, Daisuke
Akazawa, Yuko
Takeshima, Fuminao
Nakao, Kazuhiko
Fukuda, Yutaka
author_sort Fukuda, Daisuke
collection PubMed
description
format Online
Article
Text
id pubmed-4984333
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-49843332016-09-01 Safety and efficacy of Vonoprazan-based triple therapy against Helicobacter pylori infection: A single-center experience with 1118 patients Fukuda, Daisuke Akazawa, Yuko Takeshima, Fuminao Nakao, Kazuhiko Fukuda, Yutaka Therap Adv Gastroenterol Letters to the Editor SAGE Publications 2016-06-20 2016-09 /pmc/articles/PMC4984333/ /pubmed/27582888 http://dx.doi.org/10.1177/1756283X16654499 Text en © The Author(s), 2016 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Letters to the Editor
Fukuda, Daisuke
Akazawa, Yuko
Takeshima, Fuminao
Nakao, Kazuhiko
Fukuda, Yutaka
Safety and efficacy of Vonoprazan-based triple therapy against Helicobacter pylori infection: A single-center experience with 1118 patients
title Safety and efficacy of Vonoprazan-based triple therapy against Helicobacter pylori infection: A single-center experience with 1118 patients
title_full Safety and efficacy of Vonoprazan-based triple therapy against Helicobacter pylori infection: A single-center experience with 1118 patients
title_fullStr Safety and efficacy of Vonoprazan-based triple therapy against Helicobacter pylori infection: A single-center experience with 1118 patients
title_full_unstemmed Safety and efficacy of Vonoprazan-based triple therapy against Helicobacter pylori infection: A single-center experience with 1118 patients
title_short Safety and efficacy of Vonoprazan-based triple therapy against Helicobacter pylori infection: A single-center experience with 1118 patients
title_sort safety and efficacy of vonoprazan-based triple therapy against helicobacter pylori infection: a single-center experience with 1118 patients
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984333/
https://www.ncbi.nlm.nih.gov/pubmed/27582888
http://dx.doi.org/10.1177/1756283X16654499
work_keys_str_mv AT fukudadaisuke safetyandefficacyofvonoprazanbasedtripletherapyagainsthelicobacterpyloriinfectionasinglecenterexperiencewith1118patients
AT akazawayuko safetyandefficacyofvonoprazanbasedtripletherapyagainsthelicobacterpyloriinfectionasinglecenterexperiencewith1118patients
AT takeshimafuminao safetyandefficacyofvonoprazanbasedtripletherapyagainsthelicobacterpyloriinfectionasinglecenterexperiencewith1118patients
AT nakaokazuhiko safetyandefficacyofvonoprazanbasedtripletherapyagainsthelicobacterpyloriinfectionasinglecenterexperiencewith1118patients
AT fukudayutaka safetyandefficacyofvonoprazanbasedtripletherapyagainsthelicobacterpyloriinfectionasinglecenterexperiencewith1118patients